FY25 Performance
"I am pleased to update the market that we expect to report positive (adjusted) EBITDA ahead of guidance for FY25. This was driven by stronger than expected operational delivery in Q4 2025, and the contractual protections embedded within our model.
"Following the acquisition of CRS and Cryostore we now offer a full end‑to‑end service platform from preclinical through to Phase III across multiple therapeutic areas. The integration of CRS and Cryostore is complete, and we are realising synergies across our four specialist service lines. Our purpose-built full-service early phase capabilities clearly differentiate us within the market and together with our strong and diverse pipeline, we reiterate our guidance for high single digit revenue growth in 2026."
Yamin 'Mo' Khan
CEO at hVIVO
Our Purpose
Accelerate the development of safe and effective medicines that improve the lives of people around the world.
Our Mission
To constantly pursue new ways to reduce the time, risk and cost of bringing much needed life-changing medicines to market
